Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

Celsion Corporation today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology 2010 Annual Meeting.

19 Mar 2010

H1N1 flu pandemic awareness helps Americans to be better prepared this year: Survey

With almost half of respondents saying they believe a sneeze travels eight feet or more, one might think you would be sick all the time. But a recent national survey of 1,017 U.S. adult men and women (age 18+) conducted by Matrixx Initiatives, Inc., maker of Zicam, found a majority of Americans polled surprisingly saw this cold and flu season as "about the same" (42%) or only "slightly worse" (21%) from last year, despite all the hype this past fall around H1N1.

19 Mar 2010

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

Developments in nanotechnology and nanorobotics are opening up the prospects for nanomedicine and regenerative medicine where informatics and DNA computing can become the catalysts enabling health care applications at sub-molecular or atomic scales. While nanomedicine promises a new exciting frontier for clinical practice and biomedical research, issues involving cost-effectiveness studies, clinical trials and toxicity assays, drug delivery methods, and the implementation of new personalized therapies still remain challenging.

18 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

ForSight Labs licenses non-core ophthalmology technology from SurModics

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into an agreement with ForSight Labs, LLC to license certain non-core ophthalmology technology. The technology licensed in this agreement does not include the Company’s I-vation™ drug delivery technology. While the license agreement contains an up-front license fee, milestone payments and royalties, specific terms of the agreement were not disclosed.

18 Mar 2010

McGill researchers pioneer major breakthrough in DNA nanotechnology

A team of McGill Chemistry Department researchers led by Dr. Hanadi Sleiman has achieved a major breakthrough in the development of nanotubes - tiny "magic bullets" that could one day deliver drugs to specific diseased cells.

18 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.

17 Mar 2010

Trudell Medical International announces BPA free AEROCHAMBER PLUS* FLOW-VU* Chambers

Trudell Medical International is pleased to announce that AEROCHAMBER PLUS* FLOW-VU* anti-static Valved Holding Chambers are Bisphenol A Free. As always, the AEROCHAMBER PLUS* FLOW-VU* Chambers also remain free of Phthalates, Latex, Lead and PVC (Polyvinyl chloride). Trudell has recognized that consumers are beginning to voice their desire for more BPA Free products.

17 Mar 2010

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.

17 Mar 2010

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Generex Biotechnology Corporation (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Philip Raskin, MD, of The University of Texas Southwestern Medical Center in Dallas, Texas, made a presentation in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension held in Buenos Aires, Argentina, March 11-14, 2010 (www.comtecmed.com/Codhy/argentina).

17 Mar 2010

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova’s NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.

16 Mar 2010

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis.

16 Mar 2010

Lilly receives exclusive rights to commercialize Acrux's testosterone solution

Eli Lilly and Company and Acrux announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON™).

16 Mar 2010

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patent listed by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX® (choline fenofibrate) delayed-release capsules, 135 mg and 45 mg.

15 Mar 2010

Ranbaxy resolves generic Actos patent litigation

Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.

15 Mar 2010

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2009.

15 Mar 2010

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Monash Institute of Pharmaceutical Science researchers, in collaboration with the biotechnology company Starpharma Holdings Ltd have developed a new method to deliver medications that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.

15 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

Drug Delivery News and Research

Further Reading

Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010

H1N1 flu pandemic awareness helps Americans to be better prepared this year: Survey

Nanobotmodels Company offer vision of future DNA and cell-repair techniques

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

NexACT technology demonstrates ability to deliver Taxol subcutaneously

ForSight Labs licenses non-core ophthalmology technology from SurModics

McGill researchers pioneer major breakthrough in DNA nanotechnology

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Trudell Medical International announces BPA free AEROCHAMBER PLUS* FLOW-VU* Chambers

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Lilly receives exclusive rights to commercialize Acrux's testosterone solution

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Ranbaxy resolves generic Actos patent litigation

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News